Sotabase

Career

· Researcher, Berkeley Laboratory for Usable and Experimental Security (BLUES)

Publications (31)

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice
Diabetes · 2009
1,084
cited
A global metagenomic map of urban microbiomes and antimicrobial resistance
Cell · 2021
260
cited
Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.
Endocrinology · 2012
194
cited
Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus.
Endocrinology · 2001
158
cited
FGF21 Promotes Metabolic Homeostasis via White Adipose and Leptin in Mice
PLoS ONE · 2012
140
cited
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
Nature Communications · 2020
108
cited
Understanding the Physical Interactions in the FGF21/FGFR/β‐Klotho Complex: Structural Requirements and Implications in FGF21 Signaling
Chemical Biology and Drug Design · 2012
99
cited
Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors
Nature · 2013
95
cited
Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts.
Endocrinology · 2002
91
cited
Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).
Journal of Medicinal Chemistry · 2010
81
cited
GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
Cell Reports Medicine · 2021
69
cited
FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists
Journal of Bone and Mineral Research · 2017
55
cited
FGF21 acts as a negative regulator of bile acid synthesis.
Journal of Endocrinology · 2018
48
cited
2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11beta-hydroxysteriod dehydrogenase type 1.
Journal of Medicinal Chemistry · 2007
46
cited
2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Journal of Medicinal Chemistry · 2008
45
cited
Antidiabetic effects of 11β‐HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis
Diabetes, obesity and metabolism · 2009
42
cited
The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors.
Bioorganic & Medicinal Chemistry Letters · 2007
39
cited
Structural Characterization and Pharmacodynamic Effects of an Orally Active 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor
Chemical Biology and Drug Design · 2007
35
cited
Time of the day for 11β‐HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice
Diabetes, obesity and metabolism · 2009
35
cited
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept.
Journal of Medicinal Chemistry · 2014
33
cited
Sotabase
Michelle Chen | Researcher Profile | Sotabase | Sotabase